Quick-Med Technologies, Inc. Stocks

$ 0Last Updated 29.04.2026

Issuer Rating

Performance

Favourable

Risk

High

Recommendation

Sell

Market Cap

$ 18673

Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 0
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Quick-Med Technologies, Inc., a life sciences company, focuses on developing and commercializing proprietary broad-based technologies in medical and consumer healthcare markets. It specializes in the research and development of biomedical products and devices for antibacterial applications. The company's core technologies include Novel Intrinsically Micro-Bonded Utility Substrate (NIMBUS), a family of advanced polymers with antimicrobial, hemostatic, and other properties for use in a range of applications; Stay Fresh, a chemical formulation for textiles with a durable antimicrobial agent effective against an array of bacteria; and MultiStat, a family of advanced patented methods and compounds effective in skin therapy applications. It serves government agencies; and healthcare and medical, apparel and textile, and personal care companies. The company was founded in 1997 and is headquartered in Gainesville, Florida.

Company Valuation

Greatly undervalued
7/7

Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks